• BD entered a partnership with the U.S. government to expand domestic manufacturing of essential medical consumables.
• Planned investment totals $19 billion over several years, including $3 billion earmarked for U.S. manufacturing expansion.
• Targeted output increase of about 5 billion consumables a year, lifting BD’s domestically supplied share to roughly 80%.
• Deal calls for 100% of BD needles used in the U.S. to be made domestically using American-made steel.
• Agreement offers potential relief from future Section 232 tariffs on covered products, subject to final scope and milestone delivery.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BD - Becton, Dickinson and Company published the original content used to generate this news brief via PR Newswire (Ref. ID: 202610060635PR_NEWS_USPR_____NY64008) on October 06, 2026, and is solely responsible for the information contained therein.